| Summary: | Presently, there is limited data on the potential survival benefits of transurethral
resection of the prostate (TURP) in patients with metastatic hormone-sensitive
prostate cancer (mHSPCa). In this study, we aimed to assess the effects of TURP
on the survival of mHSPCa patients. Of the 59 patients diagnosed with mHSPCa
included, 28 received androgen deprivation therapy (ADT) alone, and the remaining
received TURP plus ADT. Their time to biochemical progression (TBCP) and
progression-free survival (PFS) were analyzed. Our results showed that for a
median follow-up time of 15 (range, 3–40) months and 21 (range, 6–39) months
for the ADT group and the TURP group, respectively, the TURP group exhibited
significantly longer TBCP than the ADT group (p = 0.020). In addition,
patients in the TURP group had numerically longer PFS, although the difference
between the two groups was not significantly different (p = 0.110). Cox
multivariate analysis indicated that longer TBCP was independently associated
with TURP (p = 0.032) and lower Gleason scores (p = 0.001).
Altogether this study showed that TURP could prolong TBCP and potentially improve
the PFS of mHSPCa patients. However, further studies with a larger sample size
are needed to confirm these findings.
|
|---|